Stage III Colon Cancer: Three Months or Six of Adjuvant Oxaliplatin
Early nerve symptoms on an oxaliplatin regimen force an early answer to a question IDEA was actually designed to let patients ask: does everyone need six months, or does risk category say otherwise?
A.N., a 64-year-old woman, taught piano out of her home for over thirty years and still keeps a full studio of students, though she's had to shorten lessons since starting chemotherapy. Her colon cancer was found after a positive fecal immunochemical test led to a colonoscopy; resection showed a T3N1a tumor — through the muscularis into pericolonic fat, one of fourteen nodes involved — clean margins, no high-risk histologic features noted on pathology. She is now four cycles into adjuvant CAPOX and has developed cold-triggered fingertip paresthesias after cycle three that have progressively worsened, making it hard to hold a pen or find the right piano key by feel alone — grade 2 oxaliplatin-associated peripheral neuropathy, functionally significant for the work she does with her hands.
The IDEA collaboration, a pooled analysis of six international trials, tested three months of oxaliplatin-based adjuvant therapy against the traditional six months across risk-stratified groups, and its finding was genuinely nuanced rather than a single verdict either way: three months was non-inferior to six for low-risk disease (T1–3, N1) overall, and CAPOX specifically showed less relative decrement at three months than FOLFOX did, while high-risk disease (T4 or N2) still favored six months for disease-free survival. A.N.'s tumor — T3N1a — sits inside the low-risk category IDEA studied, and she is already on CAPOX rather than FOLFOX, which is the specific combination the trial found held up best at the shorter duration. Whether that makes three months the right stopping point for her, given both the biology and the neuropathy already developing, is what today's visit is actually about. The trial's own non-inferiority margin for the low-risk group, while it held, was narrower than the confidence people often attach to it in conversation — a fact worth naming honestly rather than treating IDEA as a single clean verdict either way.
Infusion-day clinic visit, cycle four
I'd stop at three months, which she'll complete after this cycle. IDEA specifically found that for low-risk disease — T1–3, N1, exactly her stage — three months of CAPOX was non-inferior to six, with less of a decrement than the FOLFOX arm showed at the shorter duration. That's not a compromise reading of the data; it's the subgroup result that actually applies to the regimen she's on.
I take the CAPOX-specific finding seriously, but I'd point out that IDEA's non-inferiority margin for the low-risk group as a whole was narrower than people often describe it — it held, but not with a lot of room. Six months has decades of outcome data behind it. Cutting a curable cancer's treatment short to protect fine motor function in her hands is a real trade, and I don't think grade 2 neuropathy alone, however functionally significant for her work, is automatically the deciding factor over nodal-positive disease.
I'd also note the trial pools six different studies with somewhat different designs — that's not nothing when we're using it to make a call for one specific patient.
There's a middle path neither of you has named: reduce the oxaliplatin dose for the remaining cycles rather than treating this as stop-or-continue. CIPN severity tracks cumulative dose, and a reduction now, while her sensory symptoms are still grade 2 and plausibly reversible, could let her keep more of the six-month oxaliplatin exposure IDEA's high-risk data still favor, without driving toward the grade 3 threshold where recovery becomes far less likely.
Agreed: continue to cycle eight with oxaliplatin dose-reduced 20% from cycle five onward, capecitabine unchanged, and neuropathy reassessed formally before each remaining cycle with a pre-specified threshold (any progression to grade 3) that triggers stopping oxaliplatin entirely regardless of cycle count.
Not fully resolved: the medical oncologist's preference for stopping at three months was heard but not adopted as the plan, and was recorded explicitly as a reasonable alternative reading of IDEA's own low-risk CAPOX data — the group chose the dose-reduction compromise on the strength of the pharmacologist's reversibility argument, not because the case against three months was judged clearly stronger.